The reason staggering numbers are achievable (with no limit on supply) is because there is no competition, currently.
Statins were all competing with each other and in 2009 had near $40 billion combined in world wide revenue. They also got to a slow start and skepticism from the medical community when a drug similar to the first statin was found to be toxic to animals.
Vascepa doesn’t have to worry about a slow start as much because it is in effect piggy backing on current statin users. And it has the ability to do this because of it’s unprecedented 16k/QALY cost effectiveness. It’s a cheap drug and can be mass marketed to the 200 million world wide statin users. The drug will most likely not be approved for ALL statin users but as we gain momentum I believe we will be.
Imagine Lipitor coming in and having the entire statin market to itself today at brand name costs. That’s what Vascepa has or should have when approved by the FDA.
That’s why the most important thing Amarin can do is increase supply, educate consumers (DTC), and educate doctors. But really, supply will be THE limiting factor turning us into a mega blockbuster and I hope a large portion of the money raised is aimed towards this bottleneck.
So yea if 10-15 million Americans get on Vascepa, 10-15 million Europeans get on Vascepa, and another 10-15 million from the rest of the world get on Vascepa, we can surpass STAGGERING numbers in worldwide revenue. And that’s keeping it at the insanely low cost we are currently at.
It’s also why we haven’t been bought out yet. Because JT knows this (he’s mentioned 70 million people how many times now?) and will not sell the company cheap.
News 
Market Data 
Discover 
